0.00
—
Close of 27 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Globeimmune
Its shares trade under the ticker GBIM. It has been listed since 2 July 2014. In the fiscal year to 31 December 2015, it reported revenue of $6.5m and a net loss of $2.8m. At that date it held total assets of $11.5m and shareholders' equity of $3.0m.
GlobeImmune, Inc. is a biopharmaceutical company. The company is headquartered in Louisville, Colorado. The company went IPO on 2014-07-02. The firm is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The firm's segment is the business of developing and commercializing various biopharmaceutical products. The firm's infectious disease product candidates include GS-4774, which is in Phase II for the treatment of chronic hepatitis B infection; GI-19000; GI-2010, which is in the preclinical stage of development for the treatment of Human immunodeficiency virus (HIV), and GI-18000, which is in the preclinical stage of development for the treatment of Chronic hepatitis D infection. The firm's oncology product candidates include GI-6207, which is in Phase II for the treatment of medullary thyroid cancer; GI-6301, and GI-4000, which is in Phase IIb for the treatment of Resected pancreas cancer, and in Phase II for the treatment of Non-small cell lung cancer and colorectal cancer.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Jul 2014
- Employees
- 22
- Website
- globeimmune.com ↗
Leadership
Pay as last reported
- Dr. J. William FreytagIndependent Chairman of the Board
- Dr. Timothy RodellPresident, Chief Executive Officer, Director, since 2003$489,092
- Mr. C. Jeffrey DekkerVice President - Finance, Treasurer, Secretary$222,644
- Mr. Augustine LawlorIndependent Director
- Mr. Daniel MitchellIndependent Director
- Mr. S. Edward TorresIndependent Director
- Ms. Susan NoonanIR Contact Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Globeimmune Inc has a strong intellectual property portfolio, which provides the company with a competitive advantage in the biopharmaceutical industry.
- The company's innovative research and development team allows for the creation of novel and potential breakthrough immunotherapies.
Weaknesses
- Globeimmune Inc has limited financial resources, which may restrict the company's ability to fully capitalize on its innovative potential.
- The company currently lacks a diverse product portfolio, which poses a risk if one of its key product candidates fails during clinical trials.
Opportunities
- The increasing demand for effective immunotherapy treatments presents a significant growth opportunity for Globeimmune Inc.
- The partnerships and collaborations that the company has established with other industry players enable it to expand its research capabilities and market reach.
Threats
- The competitive biopharmaceutical landscape may pose challenges to Globeimmune Inc's ability to successfully bring its products to market.
- Regulatory and compliance requirements can also pose threats to the company's operations and product development timeline.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.